3

Cell state diversity promotes metastasis through heterotypic cluster formation in melanoma

bioRxiv 2020; DOI:10.1101/2020.08.24.265140

Developing a predictive signature for two trial endpoints using the cross-validated risk scores method

*arXiv* 2020; arXiv:2007.01680

A review of Bayesian perspectives on sample size derivation for confirmatory trials

*arXiv* 2020; arXiv:2006.15715

Two-stage sparse regression screening to detect biomarker-treatment interactions in randomized clinical trials

*arXiv* 2020; arXiv:2004.12028

A genome-wide association study highlights a regulatory role for IFNG-AS1 contributing to cutaneous leishmaniasis in Brazil

*bioRxiv* 2020; doi:10.1101/2020.01.13.903989

Sample size estimation using a latent variable model for mixed outcome co-primary, multiple primary and composite endpoints

*arXiv* 2019; arXiv:1912.05258

Bayesian design and analysis of external pilot trials for complex interventions

*arXiv* 2019; arXiv:1908.05955

Inherited duplications of PPP2R3B promote naevi and melanoma via a novel C21orf91-driven proliferative phenotype

bioRxiv 2019; DOI:10.1101/672576

Employing latent variable models to improve efficiency in composite endpoint analysis

*arXiv* 2019; arXiv:1902.07037

A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination

bioRxiv 2017; DOI:10.1101/195354